232 related articles for article (PubMed ID: 20708849)
21. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
[TBL] [Abstract][Full Text] [Related]
23. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
Zimmermann FB; Geinitz H; Schill S; Thamm R; Nieder C; Schratzenstaller U; Molls M
Acta Oncol; 2006; 45(7):796-801. PubMed ID: 16982542
[TBL] [Abstract][Full Text] [Related]
25. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
[TBL] [Abstract][Full Text] [Related]
26. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
[TBL] [Abstract][Full Text] [Related]
27. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).
Videtic GM; Hu C; Singh AK; Chang JY; Parker W; Olivier KR; Schild SE; Komaki R; Urbanic JJ; Timmerman RD; Choy H
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):757-64. PubMed ID: 26530743
[TBL] [Abstract][Full Text] [Related]
28. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Swaminath A; Wierzbicki M; Parpia S; Wright JR; Tsakiridis TK; Okawara GS; Kundapur V; Bujold A; Ahmed N; Hirmiz K; Kurien E; Filion E; Gabos Z; Faria S; Louie AV; Owen T; Wai E; Ramchandar K; Chan EK; Julian J; Cline K; Whelan TJ
Clin Lung Cancer; 2017 Mar; 18(2):250-254. PubMed ID: 27876603
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiation therapy for inoperable early stage lung cancer.
Timmerman R; Paulus R; Galvin J; Michalski J; Straube W; Bradley J; Fakiris A; Bezjak A; Videtic G; Johnstone D; Fowler J; Gore E; Choy H
JAMA; 2010 Mar; 303(11):1070-6. PubMed ID: 20233825
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
Onishi H; Shirato H; Nagata Y; Hiraoka M; Fujino M; Gomi K; Karasawa K; Hayakawa K; Niibe Y; Takai Y; Kimura T; Takeda A; Ouchi A; Hareyama M; Kokubo M; Kozuka T; Arimoto T; Hara R; Itami J; Araki T
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1352-8. PubMed ID: 20638194
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome.
van der Voort van Zyp NC; Prévost JB; Hoogeman MS; Praag J; van der Holt B; Levendag PC; van Klaveren RJ; Pattynama P; Nuyttens JJ
Radiother Oncol; 2009 Jun; 91(3):296-300. PubMed ID: 19297048
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience.
Lindberg K; Nyman J; Riesenfeld Källskog V; Hoyer M; Lund JÅ; Lax I; Wersäll P; Karlsson K; Friesland S; Lewensohn R
Acta Oncol; 2015; 54(8):1096-104. PubMed ID: 25813471
[TBL] [Abstract][Full Text] [Related]
33. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
34. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
36. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.
Videtic GM; Paulus R; Singh AK; Chang JY; Parker W; Olivier KR; Timmerman RD; Komaki RR; Urbanic JJ; Stephans KL; Yom SS; Robinson CG; Belani CP; Iyengar P; Ajlouni MI; Gopaul DD; Gomez Suescun JB; McGarry RC; Choy H; Bradley JD
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1077-1084. PubMed ID: 30513377
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
[No Abstract] [Full Text] [Related]
38. Stereotactic Body Radiotherapy for T3N0 Lung Cancer With Chest Wall Invasion.
Berriochoa C; Videtic GM; Woody NM; Djemil T; Zhuang T; Stephans KL
Clin Lung Cancer; 2016 Nov; 17(6):595-601. PubMed ID: 27301539
[TBL] [Abstract][Full Text] [Related]
39. Volumetric modulated arc therapy for lung stereotactic radiation therapy can achieve high local control rates.
Yamashita H; Haga A; Takahashi W; Takenaka R; Imae T; Takenaka S; Nakagawa K
Radiat Oncol; 2014 Nov; 9():243. PubMed ID: 25385062
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
Nantavithya C; Gomez DR; Wei X; Komaki R; Liao Z; Lin SH; Jeter M; Nguyen QN; Li H; Zhang X; Poenisch F; Zhu XR; Balter PA; Feng L; Choi NC; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):558-563. PubMed ID: 29680255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
